<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CAT</journal-id>
<journal-id journal-id-type="hwp">spcat</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Appl Thromb Hemost</journal-id>
<journal-title>Clinical and Applied Thrombosis/Hemostasis</journal-title>
<issn pub-type="ppub">1076-0296</issn>
<issn pub-type="epub">1938-2723</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1076029612460427</article-id>
<article-id pub-id-type="publisher-id">10.1177_1076029612460427</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letters to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Interpreting Results From Factor V Leiden Mutation Analysis</article-title>
<subtitle>A Cautionary Note</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sinclair</surname>
<given-names>Gary D.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-1076029612460427">1</xref>
<xref ref-type="aff" rid="aff2-1076029612460427">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Poon</surname>
<given-names>Man-Chiu</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-1076029612460427">3</xref>
<xref ref-type="aff" rid="aff4-1076029612460427">4</xref>
<xref ref-type="corresp" rid="corresp1-1076029612460427"/>
</contrib>
</contrib-group>
<aff id="aff1-1076029612460427"><label>1</label>Departments of Biochemistry &amp; Molecular Biology, Pathology &amp; Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada</aff>
<aff id="aff2-1076029612460427"><label>2</label>Molecular Hematology, Calgary Laboratory Services, Calgary, Alberta, Canada</aff>
<aff id="aff3-1076029612460427"><label>3</label>Departments of Medicine, Pediatrics, and Oncology, University of Calgary, Calgary, Alberta, Canada</aff>
<aff id="aff4-1076029612460427"><label>4</label>Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Foothills Hospital, Alberta Health Services, Calgary, Alberta Canada</aff>
<author-notes>
<corresp id="corresp1-1076029612460427">Man-Chiu Poon, Department of Medicine, University of Calgary Foothills Hospital, 1403-29th Street NW, Calgary, Alberta T2N 2T9, Canada Email: <email>mcpoon@ucalgary.ca</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>1</issue>
<fpage>106</fpage>
<lpage>107</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January/February 2013</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Inherited activated protein C resistance (APCR) is an autosomal dominant condition caused by a single point mutation in exon 10 of the <italic>F5</italic> gene (G to A transversion at nucleotide 1691) resulting in an arginine to glutamine substitution at amino acid 506 of the factor V protein (FV Leiden).<sup>
<xref ref-type="bibr" rid="bibr1-1076029612460427">1</xref>
</sup> This missense mutation changes the sequence of one of the activated protein C cleavage sites, suppressing factor V inactivation in vivo, and the described mechanism explains the prothrombotic tendency of individuals carrying the mutant allele.<sup><xref ref-type="bibr" rid="bibr2-1076029612460427">2</xref></sup> The effect can also be measured in vitro by a clotting assay<sup>
<xref ref-type="bibr" rid="bibr3-1076029612460427">3</xref></sup> that forms the basis of the functional APCR diagnostic test.<sup><xref ref-type="bibr" rid="bibr4-1076029612460427">4</xref></sup> Although polymerase chain reaction (PCR)-based FV Leiden mutation testing is considered the definitive diagnostic test for use in stratifying risk of deep vein thrombosis (DVT) and recurrent DVT, it remains unclear whether testing and the resultant management will improve outcomes in adults with venous thromboembolism.<sup>
<xref ref-type="bibr" rid="bibr5-1076029612460427">5</xref>
</sup> The majority of individuals with APCR have inherited the FV Leiden mutation.<sup>
<xref ref-type="bibr" rid="bibr6-1076029612460427">6</xref>
</sup> Less commonly, APCR is due to acquired conditions, such as lupus inhibitor, cancer, and pregnancy.<sup><xref ref-type="bibr" rid="bibr7-1076029612460427">7</xref></sup>
</p>
<p>Here we describe 4 different cases referred for thrombophila workup at our regional reference laboratory where results from functional and molecular testing did not correlate. In all cases, the disparity was not due to acquired APCR but because all testing were performed on peripheral blood of patients with unusual clinical histories. Case 1 was an adult female from a family with quantitative factor V deficiency. Case 2 was a young male with congenital urea cycle disorder and homozygosity for FV Leiden. He underwent a maternal (living donor) liver transplant. Case 3 was an adult male with a history of allogeneic bone marrow transplantation (allo-BMT) for acute myeloid leukemia, multiple posttransplant pulmonary embolisms, and heparin-induced thrombocytopenia. Case 4 was an adult female with no personal history of thrombosis. She underwent allo-BMT for multiple myeloma.</p>
<p>Results from functional and molecular assays are presented in <xref ref-type="table" rid="table1-1076029612460427">Table 1</xref>. The APCR assay was performed on platelet-poor plasma using a commercially available kit with factor V-deficient plasma as sample diluent (Beckman Coulter, Mississauga, Ontario, Canada) on an ACL Advance Coagulizer platform (Instrumentation Laboratory Co, Bedford, Massachusetts). This assay is highly sensitive and specific for the FV Leiden mutation. Calculated APCR ratio cutoff values of &lt;1.4 (homozygous mutant), 1.4 to 2.0 (heterozygous), and ≥2.1 (normal) were previously established by correlation of APCR ratios with the corresponding genotyping data from 375 normal (G/G), 963 heterozygous (A/G), and 40 homozygous mutant (A/A) individuals.</p>
<table-wrap id="table1-1076029612460427" position="float">
<label>Table 1.</label>
<caption>
<p>Summary of Patient Results From Peripheral Blood Specimens</p>
</caption>
<graphic alternate-form-of="table1-1076029612460427" xlink:href="10.1177_1076029612460427-table1.tif"/>
<table>
<thead>
<tr>
<th>Participants</th>
<th>APCR Ratio<sup>a</sup>
</th>
<th>FV Leiden Genotype (nt 1691)</th>
<th>Factor V Activity, IU/dL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1 </td>
<td>2.6</td>
<td>A/G</td>
<td>30</td>
</tr>
<tr>
<td>Case 2</td>
<td>1.8</td>
<td>A/A</td>
<td align="center">–</td>
</tr>
<tr>
<td>Case 3</td>
<td>1.7</td>
<td>G/G</td>
<td>–</td>
</tr>
<tr>
<td>Case 4</td>
<td>2.6</td>
<td>A/G</td>
<td>–</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1076029612460427">
<p>Abbreviations: APCR, activated protein C resistance; nt, nucleotide.</p>
</fn>
<fn id="table-fn2-1076029612460427">
<p>
<sup>a</sup> In uncomplicated situations, relationship between APCR ratio and nt 1691 genotype: ≥2.1 for G/G (normal), 1.4 to 2.0 for A/G (FV Leiden heterozygous), and &lt;1.4 for A/A (FV Leiden homozygous).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The FV Leiden molecular assay was performed on EDTA-anticoagulated peripheral blood aliquots using our previously described, whole blood allele-specific PCR assay.<sup>
<xref ref-type="bibr" rid="bibr8-1076029612460427">8</xref>
</sup>
</p>
<p>In all cases, results from our calibrated APCR assay did not reflect the determined FV Leiden genotype. In cases 1 and 4, normal ratios (&gt;2.1) were obtained, while gene testing showed heterozygosity (A/G) for the FV Leiden mutation. The individual in case 1 also had low factor V coagulant activity. In case 2, an APCR ratio of 1.8 was observed, but this individual was homozygous (A/A) for the FV Leiden mutation by molecular assay. Case 3 had an abnormal APCR ratio but genotyping demonstrated only the wild-type gene sequence (G/G).</p>
<p>Results presented can be correctly interpreted after careful consideration of the unusual clinical histories of these patients. In case 1, the phenotype can most likely be explained by heterozygosity for a rare <italic>F5</italic> gene allele carrying both an as yet uncharacterized family specific, <italic>F5</italic> gene null mutation and the FV Leiden mutation. In this kindred, expression of only the wild-type <italic>F5</italic> allele in heterozygotes (pseudohomozygous normals) will result in a normal APCR ratio but with decreased factor V coagulant activity. The proband had a normal APCR ratio (2.6) and factor V activity level of 30 IU/dL. In her family, 5 other affected family members who were heterozygous for FV Leiden were also found to have normal APCR ratios (&gt;2.1) and factor V clotting activities below the locally established normal cutoff (≥50 IU/dL), while the only available unaffected daughter with normal plasma FV activity (80 IU/dL) was homozygous for the wild-type <italic>F5</italic> gene sequence at nucleotide 1691. Our case cannot be explained by a presence of previously described <italic>F5</italic> 1690 C→T termination mutation, which causes false positive results in factor V-deficient patients using FV Leiden molecular assays based on loss of a Mnl1 restriction site,<sup>
<xref ref-type="bibr" rid="bibr9-1076029612460427">9</xref>
</sup> as our PCR assay is specific for the <italic>F5</italic> 1691 G→A mutation.<sup>
<xref ref-type="bibr" rid="bibr8-1076029612460427">8</xref>
</sup> Instead, case 1 is an alternate to the more commonly reported double heterozygosity for a <italic>F5</italic> null mutation and FV Leiden that results in pseudohomozygous FV Leiden<sup>
<xref ref-type="bibr" rid="bibr10-1076029612460427">10</xref>
</sup> and similar to one other report of a <italic>F5</italic> null/FV Leiden allele in a family with FV deficiency.<sup>
<xref ref-type="bibr" rid="bibr11-1076029612460427">11</xref>
</sup>
</p>
<p>In case 2, the liver transplant patient would be expected to have the phenotype of the donor liver, where the circulating plasma factor V is synthesized. The calculated APCR ratio is consistent with a heterozygous FV Leiden liver donor who was also his biological mother and a carrier of the FV Leiden mutation. Three further cases of disparate results from posttransplant analyses have been identified, although we were unable to directly assess the FV Leiden genotype status of anonymous liver donors.</p>
<p>Cases 3 and 4 represent other instances where the medical treatment resulted in tissue-specific chimeras. In case 3, bone marrow from a donor subsequently proven homozygous for wild-type FV was used for allo-BMT of an individual heterozygous for FV Leiden. Case 4 illustrates the alternate situation, where the normal BMT recipient was transplanted with bone marrow from a donor subsequently proven heterozygous for FV Leiden. In both cases, the APCR assay of posttransplant patient plasma reflected the recipient liver-derived FV Leiden function, while the molecular assay on peripheral blood detected the genotypes of the engrafted donor hematopoietic cells. Retrospective analysis of 290 allo-BMT donor/recipient pairs from our patient cohort has identified 5 additional instances with mismatched FV Leiden genotypes.</p>
<p>Although rare, these examples illustrate the problem of interpreting molecular data in isolation. Due to the relatively high diagnostic and prognostic impact of molecular diagnostic assays, clinicians need to recognize the importance of providing all relevant clinical history to the testing laboratory. Additionally, we suggest that results from molecular testing based on DNA from peripheral blood should be interpreted with caution in individuals with complex medical conditions and always in the context of results from functional, coagulation-based assays.</p>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-1076029612460427">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertina</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Koeleman</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Koster</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Mutation in blood coagulation factor V associated with resistance to activated protein C</article-title>. <source>Nature</source>. <year>1994</year>;<volume>369</volume>(<issue>6475</issue>):<fpage>64</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr2-1076029612460427">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoller</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Svensson</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Dahlback</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C</article-title>. <source>J Clin Invest</source>. <year>1994</year>;<volume>94</volume>(<issue>6</issue>):<fpage>2521</fpage>–<lpage>2524</lpage>.</citation>
</ref>
<ref id="bibr3-1076029612460427">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dahlback</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hildebrand</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1994</year>;<volume>91</volume>(<issue>4</issue>):<fpage>1396</fpage>–<lpage>1400</lpage>.</citation>
</ref>
<ref id="bibr4-1076029612460427">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ts’ao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Neofotistos</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Oropeza</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vahabinejad</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Finn</surname>
<given-names>WG</given-names>
</name>
</person-group>. <article-title>Modified APC-resistance test: variable ratios with respect to source of factor V-deficient plasma</article-title>. <source>Am J Hematol</source>. <year>1997</year>;<volume>54</volume>(<issue>3</issue>):<fpage>214</fpage>–<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr5-1076029612460427">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Segal</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Brotman</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Necochea</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review</article-title> <source>JAMA</source>. <year>2009</year>;<volume>301</volume>(<issue>23</issue>):<fpage>2472</fpage>–<lpage>2485</lpage>.</citation>
</ref>
<ref id="bibr6-1076029612460427">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Federman</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Kirsner</surname>
<given-names>RS</given-names>
</name>
</person-group>. <article-title>An update on hypercoagulable disorders</article-title>. <source>Arch Intern Med</source>. <year>2001</year>;<volume>161</volume>(<issue>8</issue>):<fpage>1051</fpage>–<lpage>1056</lpage>.</citation>
</ref>
<ref id="bibr7-1076029612460427">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cushman</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Epidemiology and risk factors for venous thrombosis</article-title>. <source>Semin Hematol</source>. <year>2007</year>;<volume>44</volume>(<issue>2</issue>):<fpage>62</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr8-1076029612460427">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinclair</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>MC</given-names>
</name>
</person-group>. <article-title>A hemi-nested, allele specific, whole blood PCR assay for the detection of the factor V Leiden mutation</article-title>. <source>Thromb Haemost</source>. <year>1997</year>;<volume>77</volume>(<issue>6</issue>):<fpage>1154</fpage>–<lpage>1155</lpage>.</citation>
</ref>
<ref id="bibr9-1076029612460427">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirochnik</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Halim-Kertanegara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Henniker</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>. <article-title>A novel factor V null mutation at Arg 506 causes a false positive factor V Leiden result</article-title>. <source>Thromb Haemost</source>. <year>1999</year>;<volume>82</volume>(<issue>3</issue>):<fpage>1198</fpage>–<lpage>1199</lpage>.</citation>
</ref>
<ref id="bibr10-1076029612460427">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simioni</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Castoldi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lunghi</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tormene</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rosing</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bernardi</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>An underestimated combination of opposites resulting in enhanced thrombotic tendency</article-title>. <source>Blood</source>. <year>2005</year>;<volume>106</volume>(<issue>7</issue>):<fpage>2363</fpage>–<lpage>2365</lpage>.</citation>
</ref>
<ref id="bibr11-1076029612460427">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dargaud</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Trzeciak</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Meunier</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Two novel factor V null mutations associated with activated protein C resistance phenotype/genotype discrepancy</article-title>. <source>Br J Haematol</source>. <year>2003</year>;<volume>123</volume>(<issue>2</issue>):<fpage>342</fpage>–<lpage>345</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>